Δημοσίευση στις 2019 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/29295699/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=122
, G Georgiopoulos
, D Oikonomou
, C Aggeli
, C Grassos
, D P Papadopoulos
, C Thomopoulos
, M Marketou
, K Dimitriadis
, K Toutouzas
, P Nihoyannopoulos
, C Tsioufis
, D Tousoulis
Hypertension (HT) is an important risk factor for cardiovascular disease and might precipitate pathology of the aortic valve.
To investigate the association of HT with aortic dysfunction (including both aortic regurgitation and stenosis) and the impact of antihypertensive treatment on the natural course of underlying aortic disease.
We performed a systematic review of the literature for all relevant articles assessing the correlation between HT and phenotype of aortic disease.
Co-existence of HT with aortic stenosis and aortic regurgitation is highly prevalent in hypertensive patients and predicts a worse prognosis. Certain antihypertensive agents may improve haemodynamic parameters (aortic jet velocity, aortic regurgitation volume) and remodeling of the left ventricle, but there is no strong evidence of benefit regarding clinical outcomes. Renin-angiotensin system inhibitors, among other vasodilators, are well-tolerated in aortic stenosis.
Several lines of evidence support a detrimental association between HT and aortic valve disease. Therefore, HT should be promptly treated in aortic valvulopathy. Despite conventional wisdom, specific vasodilators can be used with caution in aortic stenosis.
Valvular heart disease; aortic regurgitation; aortic stenosis; aortic valve; blood pressure; hypertension; reninangiotensin